Largest Life Science Venture Transactions in 2013

Dimension Therapeutics is a developer of new therapeutic products for people living with devastating rare and metabolic diseases associated with the liver, based on the most advanced mammalian adeno-associated virus (AAV) gene delivery technology. Dimension Therapeutics was founded in 2013 and is based in Cambridge, Massachusetts.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Regenxbio is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Regenxbio’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. Regenxbio and its third-party NAV Technology licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas. Regenxbio was founded in 2008 and is based in Rockville, Maryland.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Eurocept is a healthcare company offering a unique combination of specialty pharma and medical homecare. Eurocept Pharmaceuticals is responsible for the registration, marketing, distribution and sale of speciality medicines in the fields of anesthetics, psychiatry, urology, pediatrics and infectious diseases. Eurocept Homecare provides medical specialist homecare and related out-patient medical technology for medicine and food administration. Eurocept was founded in 2001 and is based in Houten, Netherlands.

GIMV
Investor
Private Equity Firm
Antwerp, Belgium
www.gimv.com

Respira is a pharmaceutical development company focused on commercializing its high-efficiency, dry powder inhaler (DPI) drug delivery technologies for the treatment of important diseases with unmet clinical needs. Respira was founded in 2010 and is based in Palo Alto, California.

Sun Mountain Capital
Investor
Private Equity Firm
Santa Fe, New Mexico
www.sunmountaincapital.com

OncoEthix is a privately held biotechnology company aiming to develop a small portfolio of oncology drug candidates. The Company’s lead product, OTX015, is an investigational orally administered synthetic small molecule targeted to BET bromodomain proteins 2/3/4. OTX015 was in-licensed from Mitsubishi Tanabe Pharma Corporation in March 2012 following completion of Phase I clinical studies in healthy volunteers.

Edmond de Rothschild Private Equity
Investor
Private Equity Firm
Genève, Switzerland
am.edmond-de-rothschild.com/uk/en/intermediaries-private-investors/our-expertise/private-equity

Loxo Oncology, Inc. is a biopharmaceutical company focused on the development and commercialization of highly selective medicines for patients with genomically defined cancers. Loxo Oncology, Inc. was founded in 2013 and is based in Stamford, Connecticut.

Aisling Capital
Investor
Private Equity Firm
New York, New York
www.aislingcapital.com

Lumena Pharmaceuticals is a privately-held biotechnology company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease.

Alta Partners
Investor
Venture Capital Firm
San Francisco, California
www.altapartners.com

Covagen is a clinical stage company that develops bispecific FynomAbs by fusing its human Fynomer® binding proteins to antibodies, resulting in therapeutics with novel modes of action and enhanced efficacy. Our current pipeline is focussed on the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers to multiple sites on an antibody allows Covagen to create FynomAbs with tailored architectures to maximize efficacy.

GIMV
Investor
Private Equity Firm
Antwerp, Belgium
www.gimv.com

Cydan is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential. Cydan takes advantage of recent scientific breakthroughs in rare diseases and leveraging a creative approach to drug development and operates in an externally focused, highly collaborative, and capital efficient manner. Cydan was founded in 2013 and is based in Cambridge, Massachusetts.

Bay City Capital
Investor
Venture Capital Firm
San Rafael, California
www.baycitycapital.com

PharmAkea is a biopharmaceutical company and is a developer of high-quality, small molecule drug candidates against protein targets involved in fibroproliferative diseases. PharmAkea was founded in 2012 and is based in San Diego, California.

Bay City Capital
Investor
Venture Capital Firm
San Rafael, California
www.baycitycapital.com

Celgene Corp.
Company
Life Science
Summit, New Jersey
www.celgene.com

Complix is focused on the discovery and development of alpha bodies, a novel class of biopharmaceuticals that, due to their unique structural and functional properties, are particularly suited to address disease targets that are difficult to reach with antibodies or other types of therapeutic protein scaffolds. Complix was founded in 2008 and is based in Ghent, Belguim.

GIMV
Investor
Private Equity Firm
Antwerp, Belgium
www.gimv.com

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

Galleon Pharmaceuticals engages in the pharmaceutical treatment of sleep apnea and related breathing-control disorders. Galleon Pharmaceuticals was founded in 2003 and is based in Horsham, Pennsylvania.

TPG
Investor
Private Equity Firm
Fort Worth, Texas
www.tpg.com

MPE Partners
Investor
Private Equity Firm
Cleveland, Ohio
www.mpepartners.com

Kiadis Pharma is a clinical stage biopharmaceutical company pioneering a proprietary cell-based, personalized therapy for patients with blood cancers and related disorders, an area of significant unmet medical need.Kiadis Pharma’s unique and powerful platform technology has led to an initial experimental product, ATIR™, which has already been clinically tested on sixty patients. Kiadis Pharma is based in Amsterdam, Netherlands.

Alta Partners
Investor
Venture Capital Firm
San Francisco, California
www.altapartners.com

EQT Life Sciences
Investor
Growth Capital Firm
Amsterdam, Netherlands
eqtgroup.com/private-capital/eqt-life-sciences

Avitide is a chromatography developer with diverse affinity ligand libraries and best-in-class ligand-to-resin development timelines. Avitide was formed in 2012 and is based in Lebanon, New Hampshire.

Polaris Partners
Investor
Growth Capital Firm
Boston, Massachusetts
www.polarispartners.com

Tetraphase Pharmaceuticals is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening multidrug-resistant (MDR) infections. Tetraphase Pharmaceuticals was founded in 2006 and is based in Watertown, Massachusetts.

Bay City Capital
Investor
Venture Capital Firm
San Rafael, California
www.baycitycapital.com

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Rapid Micro Biosystems is a life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. Rapid Micro Biosystems was founded in 2006 and is based in Lowell, Massachusetts.

TPG
Investor
Private Equity Firm
Fort Worth, Texas
www.tpg.com